|Cancer||Cell death||Cell cycle||Cytoskeleton||Exo/endocytosis||Differentiation||Division||Organelles||Signalling||Stem cells||Trafficking|
Cell Biology International (2002) 26, 327335 (Printed in Great Britain)
RECEPTOR-BOUND uPA IS REVERSIBLY PROTECTED FROM INHIBITION BY LOW MOLECULAR WEIGHT INHIBITORS
Kimberly D Dyera,f1, Laura A Linz‑Mcgillemb, Mary Anne Alliegrob and Mark C Alliegrob
aLaboratory of Host Defenses, NIAID, Bethesda, MD, U.S.A.
bDepartment of Cell Biology and Anatomy, Louisiana State University Health Sciences Center, New Orleans, LA, U.S.A.
Urokinase-type plasminogen activator (uPA) plays a ubiquitous role in cell migration and invasiveness. Amiloride, a competitive inhibitor of uPA, can inhibit endothelial cell (EC) outgrowth during angiogenesis. To address the question of whether amiloride blocked angiogenesis by inhibiting uPA, we undertook a study of uPA expression in sprouting EC in vitro and the effects of amiloride on both enzymatic and morphogenetic activity. As expected, amiloride inhibited soluble uPA (suPA) with an IC
Key words: angiogenesis, urokinase-type plasminogen activator, uPA, amiloride, endothelial cell, urokinase, urokinase receptor.
f1Address correspondence to: Dr Kimberly D. Dyer, Laboratory of Host Defenses, 10 Center Drive MSC 1886, Bethesda, MD 2092-1886, U.S.A.; Fax: 301-402-4369; E-mail: firstname.lastname@example.org
Received 8 May 2001; accepted 12 December 2001doi:10.1006/cbir.2001.0859